Plaque Psoriasis

A recent meta-analysis of more than 60 studies suggests guselkumab and risankizumab had the longest drug survival of IL-17 and IL-23 inhibitors for psoriasis.

In this analysis, investigators sought to assess PsA development probability in subclinical PsA as well as to characterize symptoms and patterns of subclinical PsA.

In this analysis, the study investigators highlighted the impact of smoking cigarettes on PASI 75 achievement.

These data highlight guselkumab’s impact on psoriasis patients’ symptoms and HRQoL, as well as on sexual impairment and perceptions of stigmatization.

These nationwide data contribute to the overall body of research on extraintestinal inflammatory conditions among MC patients, highlighting the value of studying the mechanisms involved.

Dr Linda Stein Gold, Dr Mona Shahriari and Dr Seemal Desai share advice for improving psoriasis care for patients with skin of color.

Dr Linda Stein Gold, Dr Mona Shahriari and Dr Seemal Desai share how they utilize biologics data from skin of color cohorts in their practice.

Drs Stein Gold and Desai share their thoughts on the early use of psoriasis systemic treatments in patients with skin of color.

This meta-analysis demonstrates the possibilities for probiotic supplementation, though additional multi-center clinical studies with larger samples may be needed.

This post-hoc analysis of clinical and real-world settings looks at both both biologic-naïve and bio-experienced individuals.

The application for generic roflumilast cream, 0.3%, for plaque psoriasis may end up entitling Padagis to 180 days of market exclusivity.

In this review of the top stories in dermatology in March, several were highlighted such as the recent report on benzene in skincare products and the FDA’s approval of spesolimab for generalized pustular psoriasis.

Experts discuss the plethora of treatment options for psoriasis, including topicals, oral therapies, phototherapy, and biologics.

Dermatology physician assistants are talking about the evolving role of their profession in taking care of patients with plaque psoriasis.

Patient Kanya Oul shares her journey to the diagnosis of generalized pustular psoriasis (GPP) and her care with dermatologist Dr Scott Boswell.

Advances practice providers TJ Chao, MPAS, PA-C and Kristine Kucera, PA-C, MPAS, DHS discuss the recent development in the treatment landscape of plaque psoriasis.

Chovatiya spoke in this post-AAD interview to some of the major takeaways in psoriasis research, highlighting deucravacitinib, bimekizumab, and other therapies.

Dermatology experts highlight VISIBLE trial results when using guselkumab in patients with skin of color.

Dr Linda Stein Gold, Dr Mona Shahriari and Dr Seemal Desai discuss VISIBLE trial, a randomized clinical trial specifically designed to examine treatment outcomes with guselkumab in patients with skin of color.

An expert in dermatology provides insight on approaching treatment in patients with plaque psoriasis who have a low BSA involvement, but with symptoms that present in difficult-to-treat areas.

Dr April W. Armstrong comments on patient selection for oral systemic treatments for plaque psoriasis management.

In this post-AAD interview, Cohen discusses his contribution to the presentation titled ‘Psoriasis: Modern Therapeutic Approaches.’

Drs Desai, Shahriari, and Stein Gold examine use and place of traditional systemic treatments in psoriasis.

Dr Stein Gold and Dr Shahriari review steroidal and non-steroidal topical treatments that are available for use in psoriasis.

April W. Armstrong, MD, MPH, shares her experience using oral systemic treatments in clinical practice for the management of plaque psoriasis.

An expert in dermatologic conditions examines laboratory requirements for initiating deucravacitinib in patients with moderate-to-severe plaque psoriasis and the impact of deucravacitinib on the treatment landscape.

Approvals by both the FDA and the Chinese NMPA have followed recent clinical trial data on spesolimab injection in GPP patients.

In this post-AAD 2024 interview, Stein Gold commented on her team’s two recent sub-analyses of the phase 4 IMMpulse studies on risankizumab for psoriasis.

Dr Linda Stein Gold and Dr Mona Shahriari discuss post-inflammatory dyspigmentation in patients with skin of color and its impact on patient’s quality of life.